Tadas S. Vasaitis

Novel C-17-Heteroaryl Steroidal CYP17 Inhibitors/Antiandrogens:  Synthesis, in Vitro Biological Activity, Pharmacokinetics, and Antitumor Activity in the LAPC4 Human Prostate Cancer Xenograft Model

Venkatesh Handratta, Tadas S. Vasaitis, Vincent C.O. Njar et al. · Journal of Medicinal Chemistry · 2005 · 247 citations · Full text

Pharmacy, Medicinal Chemistry, Pharmacology +17

Androgen receptor inactivation contributes to antitumor efficacy of 17α-hydroxylase/17,20-lyase inhibitor 3β-hydroxy-17-(1<i>H</i>-benzimidazole-1-yl)androsta-5,16-diene in prostate cancer

Tadas S. Vasaitis, Aashvini Belosay, Adam Schayowitz et al. · Molecular Cancer Therapeutics · 2008 · 135 citations · Full text

Medicine, Oncology, Pharmacology +17

Systematic Structure Modifications of Multitarget Prostate Cancer Drug Candidate Galeterone To Produce Novel Androgen Receptor Down-Regulating Agents as an Approach to Treatment of Advanced Prostate Cancer

Puranik Purushottamachar, Abhijit M. Godbole, Lalji K. Gediya et al. · Journal of Medicinal Chemistry · 2013 · 103 citations · Full text

Pharmacy, Medicinal Chemistry, Pharmacology +17

Three Dimensional Pharmacophore Modeling of Human CYP17 Inhibitors. Potential Agents for Prostate Cancer Therapy

Omoshile Clement, C. M. Freeman, Rolf W. Hartmann et al. · Journal of Medicinal Chemistry · 2003 · 83 citations · Full text

Pharmacy, Medicinal Chemistry, Pharmacology +17

Synthesis and biological evaluations of putative metabolically stable analogs of VN/124-1 (TOK-001): Head to head anti-tumor efficacy evaluation of VN/124-1 (TOK-001) and abiraterone in LAPC-4 human prostate cancer xenograft model

Robert D. Bruno, Tadas S. Vasaitis, Lalji K. Gediya et al. · Steroids · 2011 · 76 citations · Full text

Medicine, Oncology, Pharmacology +15